Rituximab – USA

Rituximab – USA

Decision on IPR: Nov 08, 2018

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Status
IPR2018-00186
12/01/2017
06/14/2018
Pfizer, Inc.
9,296,821
Biogen Inc.
Terminated
On US’821 patent, Celltrion previously filed IPR (IPR2017-01095) in which Board on Oct 04, 2018 issued final written decision & found claims 1-6 unpatentable.

US 9,296,821 (Biogen Inc; Exp: Jun 11, 2019) – Non OB

1. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m2 of rituximab, and wherein the method provides a beneficial synergistic effect in the patient.
2. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of C2B8 during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy).
3. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of a chimeric anti-CD20 antibody during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences.
4. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m.sup.2 of rituximab once every 3 weeks for 8 doses, and wherein the method provides a beneficial synergistic effect in the patient.
5. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of C2B8 once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy).
6. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of a chimeric anti-CD20 antibody once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved